Quantification of hematopoietic stem and progenitor cells by targeted DNA methylation analysis

• Published in: Clinical epigenetics Vol. 15; no. 1; p. 105
• Main Authors: Bocova, Ledio, Hubens, Wouter, Engel, Cordula, Koschmieder, Steffen, Jost, Edgar, Wagner, Wolfgang
• Format: Journal Article
• Language: English
• Published: Germany BioMed Central Ltd 27-06-2023; BioMed Central; BMC
• Subjects: Analysis; Antigens, CD34 - metabolism; Apheresis; Apoptosis Regulatory Proteins; B cells; Biomarker; Biomarkers; Blood diseases; Bone marrow; Brief Report; CD34; CD34 antigen; CpG islands; DNA; DNA Methylation; Epigenetic; Epigenetic inheritance; Epigenetics; Flow cytometry; Gene expression; Granulocyte Colony-Stimulating Factor; Hematopoietic stem cells; Hematopoietic Stem Cells - metabolism; Hemopoiesis; HSC; Humans; Kinases; Leukemia; Leukemia - metabolism; Leukocytes; Methylation; Peripheral blood; Progenitor cells; Protein Serine-Threonine Kinases; Stem cells; Biomarker; Leukemia; DNA methylation; HSC; Epigenetic; Blast; CD34; Hematopoietic stem cells
• ISSN: 1868-7083; 1868-7075; 1868-7083; 1868-7075
• DOI: 10.1186/s13148-023-01521-w

Hematopoietic stem and progenitor cells (HSPCs) are quantified in daily clinical practice by flow cytometry. In this study, we provide proof of concept that HSPCs can also be estimated by targeted DNA methylation (DNAm) analysis. The DNAm levels at three individual CG dinucleotides (CpG sites) in the genes MYO1D, STK17A, and SP140 correlated with CD34
cell numbers in mobilized peripheral blood and with blast counts in leukemia. In the future, such epigenetic biomarkers can support the evaluation of stem cell mobilization, HSPC harvesting, or blast count in leukemia.